CAS No. : 71963-77-4
(Synonyms: Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224)
| Size | Price | Stock |
|---|---|---|
| 100mg | $66 | In-stock |
| 500mg | $86 | In-stock |
| 1 g | Get quote | |
| 5 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N0402 |
| M.Wt: | 298.37 |
| Formula: | C16H26O5 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic);H2O : < 0.1 mg/mL |
Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria[1].
In Vitro: Artemether (0-200 μg/mL, 24-72 h) inhibits rat C6 glioma cell growth in a dose- and time-dependent manner[2].
Artemether (0-10 μM, 72 h) inhibits RANKL-induced osteoclast (osteoclast precursor cells (BMMs)) formation and related gene expression (TRAP, NFATc1, V-ATPase-d2, CTSK, DC-STAMP, MMP-9)[2].
Artemether (48 or 96 h) inhibits ConA- or alloantigen-induced BALB/c splenocyte proliferation (IC50: 6.3 and 3.5 μM)[4].
Artemether (0-50 μM, 16-36 h) inhibits production of the IL-2 and IFN-γ in BALB/c splenocyte[4].
Artemether (0-50 μM, 72 h) inhibits ConA-induced splenocyte, CD4+T- and CD8+ T-cell divisions, and inhibits cell cycle progression through G1/S transition[4].
In Vivo: Artemether (0-66 mg/kg, p.o.) inhibits tumor growth and angiogenesis in SD rats bearing C6 glioma cells[2].
Artemether (10 mg/kg, i.p., 8 days) protects mice against LPS-induced osteolytic bone loss[3].
Artemether (50 and 100 mg/kg, p.o.) inhibits T-cell-mediated immune responses (ear swelling) in DNFB-induced DTH model in BALB/c mice[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.